This company listing is no longer active
0CB Stock Overview
A pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Oxford Cannabinoid Technologies Holdings Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.001 |
| 52 Week High | UK£0.01 |
| 52 Week Low | UK£0.001 |
| Beta | 0.60 |
| 1 Month Change | 0% |
| 3 Month Change | -80.00% |
| 1 Year Change | -90.91% |
| 3 Year Change | -98.18% |
| 5 Year Change | n/a |
| Change since IPO | -98.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0CB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -2.0% |
| 1Y | -90.9% | -15.8% | 6.8% |
Return vs Industry: 0CB underperformed the German Pharmaceuticals industry which returned -17.6% over the past year.
Return vs Market: 0CB underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 0CB volatility | |
|---|---|
| 0CB Average Weekly Movement | 22.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0CB's share price has been volatile over the past 3 months.
Volatility Over Time: 0CB's weekly volatility has decreased from 50% to 22% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 7 | Clarissa Sowemimo-Coker | www.oxcantech.com |
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase – I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia.
Oxford Cannabinoid Technologies Holdings Plc Fundamentals Summary
| 0CB fundamental statistics | |
|---|---|
| Market cap | €1.47m |
| Earnings (TTM) | -€4.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 0CB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0CB income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£2.33m |
| Gross Profit | -UK£2.33m |
| Other Expenses | UK£1.91m |
| Earnings | -UK£4.24m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0CB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/07 20:23 |
| End of Day Share Price | 2024/06/06 00:00 |
| Earnings | 2023/10/31 |
| Annual Earnings | 2023/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oxford Cannabinoid Technologies Holdings Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |